3SBIO (01530) shares climbed more than 7% in early trading, with the stock last up 6.85% at HK$17.63, on turnover of HK$395 million. The surge follows the company's release of its 2026 interim results, which showed solid underlying earnings momentum despite a headline profit dip.

For the first half, the biopharmaceutical firm reported total revenue of RMB 4.53 billion, up 3.9% year-on-year. Net profit attributable to shareholders fell 15.58% to RMB 1.15 billion, but adjusted operating net profit attributable to shareholders rose 26.5% to RMB 1.44 billion, underscoring stronger core business performance.

The company noted that its key product portfolio has now secured marketing approvals in 23 countries globally, with overseas product sales growing 43% year-on-year. This expansion was driven by increased market penetration across multiple emerging economies for its core products, including rhEPO, Yisaipu, and rhTPO.

Management stated that the company does not expect currency fluctuations to have a material adverse impact on its operations in the foreseeable future.